Drug Use and Addiction
Also known as: Drug abuse, Substance Use
Methodology & AI Transparency ⓘ
Drug Use and Addiction Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are drugs? Drugs are chemical substances that can change how your body and mind work.
- 2 Real-world patient consensus: Diagnostic registry F90.7: Drug Use and Addiction is managed within ADHD & Focus (aka Drug abuse).
- 3 Typical cash cost range: Primary evaluation for Drug Use and Addiction incorporates sleep-apnea/mood comorbidity screening [Drug Use and Addiction F90.7] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Drug Use and Addiction: maintaining ASRS-v1.1 / Vanderbilt in Drug Use and Addiction (F90.7: Executive Score) within Functional symptom control (F90.7).
Ask our AI Specialists anything about Drug Use and Addiction
What Is Drug Use and Addiction?
What are drugs? Drugs are chemical substances that can change how your body and mind work. They include prescription medicines, over-the-counter medicines , alcohol , tobacco , and illegal drugs. What is drug use? Drug use, or misuse, includes: Using illegal substances, such as: Anabolic steroids Club drugs Cocaine Heroin Inhalants Cannabis (also known as marijuana) Methamphetamines Misusing prescription medicines , including opioids . This means taking the medicines in a different way than your health care provider prescribed. This includes Taking a medicine that was prescribed for someone else. Taking a larger dose than you are supposed to.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Drug Use and Addiction (code F90.7) is default-mode network intrusion [Drug Use and Addiction F90.7], Cross-referenced with NIH MeSH (Drug Misuse, Substance-Related Disorders), which ADHD, Autism & Behavioral Health clinicians address while surveilling ASRS-v1.1 / Vanderbilt in Drug Use and Addiction (F90.7: Executive Score) (Functional symptom control (F90.7)).
Common Symptoms & Clinical Signs
- • Using illegal substances, such as: • Anabolic steroids
- • Cannabis (also known as marijuana)
- • Presentation of Drug Use and Addiction (F90.7): time blindness, working-memory in Drug Use and Addiction (F90.7: slips, and chronic)
- • Secondary Drug Use and Addiction clinical sign: internal restlessness, impulsive in Drug Use and Addiction (F90.7: interrupting, or emotional)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Drug Use and Addiction Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F90.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | ADHD, Autism & Behavioral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ASRS-v1.1 / Vanderbilt in Drug Use and Addiction (F90.7: Executive Score) | Functional symptom control (F90.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Blood Pressure in Drug Use and Addiction (F90.7: & Pulse (on) | < 125/80 mmHg; HR < 85 bpm (F90.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Drug Use and Addiction (F90.7: Iron Saturation) | Ferritin 50 – 120 ng/mL (F90.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Drug Use and Addiction
Treatment selection for Drug Use and Addiction depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Drug Use and Addiction)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy and tolerability of antidepressant drugs in treatment of depression in: What a 6,949-Participant Study Found A total of 33 RCTs were included in 32 articles, involving 6949 patients. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences • 2022-08-01 • Meta-Analysis | N = 6,949 | 99/100 | PMID 37202104 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Benefits and safety of anti-prediabetic drugs in patients with prediabetes: a: What a 16,610-Participant Study Found Among all the included interventions, GLP-1RAs, GIP/GLP-1RAs, and TZDs demonstrated favorable anti-prediabetic efficacy and acceptable safety. BMC medicine • 2026-02-19 • Meta-Analysis | N = 16,610 | 99/100 | PMID 41715123 ↗ |
| New Insights on Comparative efficacy and acceptability of anxiolytic drugs for the treatment of: What a 28,637-Participant Study Found This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. European archives of psychiatry and clinical neuroscience • 2026-06-15 • Meta-Analysis | N = 28,637 | 99/100 | PMID 40788541 ↗ |
| New Insights on Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus: What a 1,306-Participant Study Found Participants with suboptimal (<85%) staying on track with medication to B/F/TAF maintained high levels of VS, whereas suboptimal DTG + 2 NRTI staying on track with medication was associated with lower VS. The Journal of antimicrobial chemotherapy • 2025-01-03 • Phase III Randomized Trial | N = 1,306 | 96/100 | PMID 39556192 ↗ |
Drug Use and Addiction Patient Community & “People Like Me” Threads
Filter Drug Use and Addiction community threads and patient logs by age, biological sex, dosage, and treatment duration.